Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b698c934c4b923aa5bc9e441eb68d5d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
filingDate |
2020-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c456251b43f1e8ba61134949f49f383 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96957323d8883ae9e28289af9c278d4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f050cdb24c419a5f6e4b930f0f120e7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c4679cd85b39518e2b414c6538f263cf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9a428850facdb1ae27e2aabaadb1938 |
publicationDate |
2020-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2020172510-A |
titleOfInvention |
Compounds for drug combination therapy for cancer |
abstract |
PROBLEM TO BE SOLVED: To provide a therapeutic agent for cancer. SOLUTION: The first therapeutic agent containing compound (1) or a pharmaceutically acceptable salt thereof is administered in combination with (ii) a second therapeutic agent, and the first therapeutic agent and the first therapeutic agent. A method of treatment in which the two therapeutic agents are administered simultaneously or sequentially. [Selection diagram] Fig. 1 |
priorityDate |
2013-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |